Showing 1 - 5 results of 5 for search 'Sheida Hayati', query time: 0.02s Refine Results
  1. 1
    Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia

    Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia by Laura W. Dillon, Sheida Hayati, Gregory W. Roloff, Ilker Tunc, Mehdi Pirooznia, Antonina Mitrofanova, Christopher S. Hourigan

    Published 2019-02-01
    Get full text
    Article
  2. 2
    P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY

    P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY by Uwe Platzbecker, Sheida Hayati, Aarif Ahsan, Amit Verma, Srinivas Aluri, Shelonitda Rose, Anita Gandhi, Rajasekhar Nvs Suragani, Sadanand Vodala

    Published 2023-08-01
    Get full text
    Article
  3. 3
    P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS

    P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS by Danny Jeyaraju, Sheida Hayati, Ann Polonskaia, Andrew Browne, Alberto Risueño, Patrick Hagner, Vikas Gupta, Moshe Talpaz, Christopher Hernandez, Vincent Chia, Patrick Brown, Daniel Lopes De Menezes, Ross La Motte-Mohs, Rajasekhar Nvs Suragani, Anita Gandhi

    Published 2023-08-01
    Get full text
    Article
  4. 4
    P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY

    P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY by Srinivas Aluri, Aarif Ahsan, Sheida Hayati, Manuel Ugidos, Punit Shah, Kate Lizotte, Samarpana Chakraborty, Kith Pradhan, Srabani Sahu, Shahina Maqbool, Aditi Shastri, Ashok Dongre, Uwe Platzbecker, Anita Gandhi, Rajasekhar Nvs Suragani, Sadanand Vodala, Amit Verma

    Published 2023-08-01
    Get full text
    Article
  5. 5
    S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY

    S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM... by Matteo Giovanni Della Porta, Uwe Platzbecker, Valeria Santini, Amer M. Zeidan, Pierre Fenaux, Rami S. Komrokji, Jake Shortt, David Valcárcel, Anna Jonášová, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui LI, Jennie Zhang, Ana Carolina Giuseppi, Sandra Kreitz, Veronika Pozharskaya, Karen L. Keeperman, Shelonitda Rose, Jeevan K. Shetty, Sheida Hayati, Sadanand Vodala, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Guillermo Garcia-Manero

    Published 2023-08-01
    Get full text
    Article

Search Tools: